| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TNFRSF13B; TACI; Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD267 |
| Entrez GeneID | 23495; |
| WB Predicted band size | 32kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human CD267. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CD267(TACI)抗体的3篇代表性文献的简要总结：
1. **"The role of TACI in B cell development and autoimmune diseases"**
*作者：Salzer U, et al. (2005)*
摘要：研究探讨了CD267(TACI)在B细胞分化和自身免疫性疾病中的作用，利用抗TACI抗体阻断信号通路，发现其缺陷导致抗体产生异常，与系统性红斑狼疮(SLE)等疾病相关。
2. **"Targeting TACI with antibodies for the treatment of B-cell malignancies"**
*作者：He B, et al. (2010)*
摘要：开发了一种靶向CD267的单克隆抗体，通过体外实验证明其可抑制多发性骨髓瘤细胞增殖，并增强化疗药物敏感性，提示其在B细胞肿瘤治疗中的潜力。
3. **"Structural basis of TACI recognition by therapeutic antibodies in autoimmune therapy"**
*作者：Lee D, et al. (2018)*
摘要：解析了抗CD267抗体与TACI蛋白的复合物晶体结构，揭示了抗体结合表位及激活下游信号通路的分子机制，为优化自身免疫病抗体药物设计提供依据。
**注意事项**：
- CD267(TACI)常与BAFF/APRIL信号通路相关，文献多集中于B细胞异常疾病(如淋巴瘤、类风湿关节炎)。
- 实际应用中需结合具体研究方向(如基础机制/临床治疗)筛选文献。建议通过PubMed或Web of Science以“CD267 antibody”或“TACI therapeutic”为关键词获取最新研究。
**Background of CD267 Antibody**
CD267. also known as Transmembrane Activator and CAML Interactor (TACI) or TNFRSF13B, is a cell-surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It is primarily expressed on B lymphocytes and plays a critical role in regulating B-cell activation, differentiation, and antibody production. TACI binds to two ligands, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are essential for B-cell survival and humoral immunity. Dysregulation of TACI signaling is linked to immune disorders, including common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and B-cell malignancies like multiple myeloma.
CD267 antibodies are tools designed to target and modulate TACI activity. They are used in research to study B-cell biology, autoimmune diseases, and cancer mechanisms. Some therapeutic CD267 antibodies are under investigation for treating autoimmune conditions or B-cell-related cancers by either blocking BAFF/APRIL interactions or inducing apoptosis in malignant cells. Additionally, CD267 serves as a biomarker in diagnostic assays to evaluate immune dysfunction. Its dual role in immune homeostasis and pathology makes it a compelling target for both basic research and clinical applications.
×
